Post Market Clinical Follow-Up TOUCH® CMC 1

Inclusion Criteria: * Adult patients (age ≥ 18 years), * Patients suffering from rhizarthrosis (I - IV based on the Dell classification), * Pain \>3 on the VAS scale, * Patients to undergo a replacement of the trapeziometacarpal joint with the Touch® dual mobility trapeziometacarpal prosthesis. Exclusion Criteria: * Pregnant women, * Patients with contraindications to surgery in general, * Patients suffering from Temporary Regional Pain Syndrome (TRPS), * Patients with a severe or chronic, local or systemic infection, * Patients with severe muscle, neurological or vascular impairments affecting the trapezium-metacarpal joint, * Patients with bone demineralization or destruction that may affect the proper fixation of the implant, * Patients whose bone dimensions are incompatible with the implant dimensions, * The combination of the Touch® prosthesis with other components of another origin is not authorized, * Patients with allergies to the components of the product or with known allergies (chromium, cobalt, nickel), * Patients with an intellectual disability who cannot, therefore, follow the instructions of their surgeon, * Patient with scaphoid-trapezium-trapezoid (STT) arthritis, * Patient requiring revision of a trapeziometacarpal prosthesis, * Patient who has undergone a TMC joint infiltration within 3 months of the expected date of replacement of the joint with a Touch® prosthesis.